Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin

National University Health System (NUHS)

Status: Unknown

Conditions: Infections Requiring Prolonged Duration (>10 Days) of Vancomycin

Treatments: Drug: continuous vancomycin infusion; Drug: intermittent vancomycin infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT01720940

NUHID-001

Details and patient eligibility

About

This study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion.

This study will recruit 220 subjects from 2 hospitals over a period of 3 years.

Participants are invited if they have an infection that requires prolonged vancomycin therapy (> more than 10 days).

Enrollment: 220 estimated patients

Sex: All

Ages: 21 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults aged 21-80 years
• Documented infection requiring prolonged (> 10 days) of vancomycin therapy
• Creatinine clearance > 50 ml/min (using Cockroft-Gault equation)

Exclusion criteria

• Patient already received 7 days or more of vancomycin therapy
• Pregnancy
• Severe burns > 40% body surface area
• Spinal cord injuries
• Participation in another interventional trial in previous 30 days
• Inability to obtain informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

220 participants in 2 patient groups

continuous vancomycin infusion

Experimental group

Treatment:

Drug: continuous vancomycin infusion

intermittent vancomycin infusion

Active Comparator group

Description:

vancomycin in this arm will be administered as intermittent infusion

Treatment:

Drug: intermittent vancomycin infusion